Industry / DCVMN / PhRMA / EFPIA / IFPMA / BIO Watch [to 11 July 2015]

:: PhRMA Statement on House Passage of 21st Century Cures Act
Washington, D.C. (July 10, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive officer John J. Castellani issued the following statement on passage of the 21st Century Cures Act (H.R. 6) by the U.S. House of Representatives:
“PhRMA applauds the House of Representatives for the overwhelming passage of the 21st Century Cures Act and looks forward to continuing our work with the Senate to ensure biomedical advances continue and are available to the patients who need them to live longer, healthier lives.

:: Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery
July 07, 2015
Pfizer Inc. (NYSE: PFE) announced today enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510)…